Article Text

Download PDFPDF

Practical metrics for establishing the health benefits of research to support research prioritisation
  1. Beth Woods1,
  2. Laetitia Schmitt1,
  3. Claire Rothery1,
  4. Andrew Phillips2,
  5. Timothy B Hallett3,
  6. Paul Revill1,
  7. Karl Claxton1
  1. 1Centre for Health Economics, University of York, York, Yorkshire, UK
  2. 2Institute for Global Health, University College London, London, UK
  3. 3Department of Infectious Disease Epidemiology, Imperial College London, London, London, UK
  1. Correspondence to Beth Woods; beth.woods{at}york.ac.uk

Abstract

Introduction We present practical metrics for estimating the expected health benefits of specific research proposals. These can be used by research funders, researchers and healthcare decision-makers within low-income and middle-income countries to support evidence-based research prioritisation.

Methods The methods require three key assessments: (1) the current level of uncertainty around the endpoints the proposed study will measure; (2) how uncertainty impacts on the health benefits and costs of healthcare programmes and (3) the health opportunity costs imposed by programme costs. Research is valuable because it can improve health by informing the choice of which programmes should be implemented. We provide a Microsoft Excel tool to allow readers to generate estimates of the health benefits of research studies based on these three assessments. The tool can be populated using existing studies, existing cost-effectiveness models and expert opinion. Where such evidence is not available, the tool can quantify the value of research under different assumptions. Estimates of the health benefits of research can be considered alongside research costs, and the consequences of delaying implementation until research reports, to determine whether research is worthwhile. We illustrate the method using a case study of research on HIV self-testing programmes in Malawi. This analysis combines data from the literature with outputs from the HIV synthesis model.

Results For this case study, we found a costing study that could be completed and inform decision making within 1 year offered the highest health benefits (67 000 disability-adjusted life years (DALYs) averted). Research on outcomes improved population health to a lesser extent (12 000 DALYs averted) and only if carried out alongside programme implementation.

Conclusion Our work provides a method for estimating the health benefits of research in a practical and timely fashion. This can be used to support accountable use of research funds.

  • HIV
  • health economics
  • health services research
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Handling editor Seye Abimbola

  • Twitter @bs_woods

  • Contributors All authors conceived of and planned the paper, reviewed analysis results, and reviewed and edited the manuscript. BW and LS conducted the analysis. BW wrote the manuscript.

  • Funding This study was funded by the HIV Modelling Consortium, which is funded by a grant from the Bill & Melinda Gates Foundation to Imperial College London and by the Thanzi la Onse project, which is funded through the Medical Research Council Global Challenges Research Fund. In addition, TBH acknowledges joint Centre funding from the UK Medical Research Council and Department for International Development.

  • Competing interests All authors had financial support from the Bill & Melinda Gates Foundation and Medical Research Council Global Challenges Research Fund. TBH received joint Centre funding from the UK Medical Research Council and Department for International Development. In addition, TBH reports grants from the Bill & Melinda Gates Foundation, WHO and Medical Research Council, and personal fees from the Bill & Melinda Gates Foundation, the Global Fund and World Health Organisation, outside the submitted work.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement No additional data are available as this study is based on an analysis of transmission model outputs.